Researchers say the jury is still out on whether the immunotherapy drug tremelimumab will offer enough benefits to be worth the cost for mesothelioma patients.(PRWeb November 16, 2015)Read the full story at http://www.prweb.com/releases/2015/11/prweb13082279.htm (Source: PRWeb: Medical Pharmaceuticals)
from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=151107178&cid=c_409_34_f&fid=22564&url=http%3A%2F%2Fwww.prweb.com%2Freleases%2F2015%2F11%2Fprweb13082279.htm
Newly-Published Review of Promising Mesothelioma Drug Finds Value...
ad
Enregistrer un commentaire